This article is more than 5 years old. Information may no longer be current.

VIDEO: ODs must stay up-to-date on new OSD technologies

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Jacob Lang, OD, said here at the Twin Cities Ocular Surface Disease symposium that new devices for diagnosing and treating ocular surface diseases are evolving every day.

In particular, neurostimulation with the TrueTear (Allergan) device can increase tears and proteins and activate the lipids, he said.

Disclosure: Lang reported that he has received honorarium from Allergan and Shire and that he is an advisory board member for Shire.